X4 Pharmaceuticals Inc Asset Turnover Ratio (XFOR), as of first quarter 2026, current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
X4 Pharmaceuticals Inc  (NASDAQ: XFOR)
 

X4 Pharmaceuticals Inc Asset Turnover Ratio

Quarterly Results, Trends, Rankings, Statistics

X4 Pharmaceuticals Inc's asset turnover ratio, the ratio that measures the ability of X4 Pharmaceuticals Inc's assets to generate revenue, sequentially decreased to 0.04 in the first quarter (Mar 31 2026), which does not come as a surprise, as the X4 Pharmaceuticals Inc continue to experience difficult business climate.

Within sector 58 more businesses have achieved higher asset turnover ratio. While ranking the asset turnover ratio, among all other companies, it is fair to say, that the company's position has deteriorated in the First Quarter 2026 compared to the preceding quarter from 2566 to 3363.

Asset Turnover Ratio Definition


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

XFOR Asset Turnover Ratio (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Asset Change 107.89 % 98.34 % -8.2 % -50.07 % 15.89 %
Y / Y Revenue Change -90.6 % 79.08 % 215.18 % 250.44 % -
Asset Turnover Ratio (TTM) 0.04 0.2 0.25 0.23 0.19
XFOR's Total Ranking # 3363 # 2566 # 315 # 2467 # 125
Seq. Asset Change -6.95 % 77.59 % 55.52 % -19.11 % -11.22 %
Seq. Revenue Change 5.45 % 45.5 % -10.54 % -93.15 % 1908.86 %



Asset Turnover Ratio Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 59
Healthcare Sector # 505
Overall Market # 3363

Asset Turnover Ratio Statistics
High Average Low
0.25 0.18 0.04
(Sep 30 2025)   (Mar 31 2026)




XFOR Company Profile • Back to XFOR Efficiency Comparisons • Compare XFOR Asset Turnover Ratio to its Competitors



Companies with similar Asset Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector Asset Turnover Ratio Revenues for 12 Months ending Mar 31 2026 Assets at quarter ending Mar 31 2026
Abeona Therapeutics Inc   0.09 $ 20.140  Millions$ 223.848  Millions
Therapeuticsmd Inc   0.09 $ 3.353  Millions$ 38.103  Millions
Ocular Therapeutix Inc   0.09 $ 52.038  Millions$ 600.700  Millions
Monte Rosa Therapeutics Inc   0.09 $ 42.953  Millions$ 501.129  Millions
Bicycle Therapeutics Plc  0.09 $ 63.496  Millions$ 741.533  Millions
Ocugen Inc   0.08 $ 4.465  Millions$ 52.903  Millions
Lenz Therapeutics Inc   0.08 $ 20.989  Millions$ 251.612  Millions
Stoke Therapeutics Inc   0.08 $ 32.080  Millions$ 401.621  Millions
Keros Therapeutics Inc   0.08 $ 42.450  Millions$ 537.566  Millions
Cytokinetics Incorporated  0.08 $ 105.815  Millions$ 1,340.052  Millions
Intellia Therapeutics Inc   0.08 $ 66.092  Millions$ 856.269  Millions
Longeveron Inc   0.08 $ 1.216  Millions$ 15.944  Millions
Tonix Pharmaceuticals Holding Corp   0.07 $ 17.556  Millions$ 243.721  Millions
Surrozen Inc   0.07 $ 7.494  Millions$ 104.044  Millions
Armata Pharmaceuticals Inc   0.07 $ 5.693  Millions$ 79.247  Millions
Biorestorative Therapies Inc   0.06 $ 0.363  Millions$ 5.720  Millions
Vir Biotechnology Inc   0.06 $ 65.495  Millions$ 1,060.098  Millions
Agape Atp Corporation  0.06 $ 1.509  Millions$ 24.653  Millions
Caribou Biosciences Inc   0.06 $ 11.203  Millions$ 185.063  Millions
Alector Inc   0.06 $ 18.417  Millions$ 306.215  Millions
Prophase Labs Inc   0.06 $ 3.386  Millions$ 56.586  Millions
Abcellera Biologics Inc   0.06 $ 79.208  Millions$ 1,355.529  Millions
Grail Inc   0.06 $ 156.120  Millions$ 2,757.268  Millions
Nexalin Technology Inc   0.06 $ 0.276  Millions$ 5.005  Millions
Kyntra Bio Inc   0.05 $ 7.439  Millions$ 136.073  Millions
Agios Pharmaceuticals Inc   0.05 $ 66.048  Millions$ 1,334.789  Millions
Insight Molecular Diagnostics Inc   0.05 $ 1.949  Millions$ 40.159  Millions
Recursion Pharmaceuticals Inc   0.05 $ 66.408  Millions$ 1,378.883  Millions
Seer Inc   0.05 $ 14.386  Millions$ 299.828  Millions
Aligos Therapeutics Inc   0.05 $ 4.705  Millions$ 99.390  Millions



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.